The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24)

Abstract To investigate the potential benefits of acarbose therapy on cardiovascular events (CVD) in Type 2 diabetes (T2DM) in an urban community over 10-year follow-up. The study population of Beijing Community Diabetes Study (BCDS) were type 2 diabetes (T2DM) living in 21 communities in Beijing. A...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xue-Lian Zhang, Shen-Yuan Yuan, Gang Wan, Ming-Xia Yuan, Guang-Ran Yang, Han-Jing Fu, Liang-Xiang Zhu, Jian-Dong Zhang, Yu-Ling Li, Da-yong Gao, Xue-Li Cui, Zi-ming Wang, Rong-Rong Xie, Ying-jun Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9dd8a1e1dbfc45a38f9200035a914351
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9dd8a1e1dbfc45a38f9200035a914351
record_format	dspace
spelling	oai:doaj.org-article:9dd8a1e1dbfc45a38f9200035a9143512021-12-02T13:30:51ZThe effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24)10.1038/s41598-021-84015-02045-2322https://doaj.org/article/9dd8a1e1dbfc45a38f9200035a9143512021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84015-0https://doaj.org/toc/2045-2322Abstract To investigate the potential benefits of acarbose therapy on cardiovascular events (CVD) in Type 2 diabetes (T2DM) in an urban community over 10-year follow-up. The study population of Beijing Community Diabetes Study (BCDS) were type 2 diabetes (T2DM) living in 21 communities in Beijing. All patients received comprehensive intervention in accordance with the Chinese guidelines for the prevention and treatment of diabetes. Professors in endocrinology from top tier hospitals regularly visited the communities for consultations, which was a feature of this study. A total of 1797 T2DM in BCDS study had complete screening data, including blood glucose, blood pressure, lipid profiles and acarbose continuous therapy. After 10-year follow-up, the risks of CVD outcomes were assessed according to whether patients had received acarbose therapy or not. All patients were followed-up to assess the long-term effects of the multifactorial interventions. At baseline, compared with the acarbose therapy free in T2DM, there was no significant difference in achieving the joint target control in patients with acarbose therapy. From the beginning of 8th year follow-up, the joint target control rate in patients with acarbose therapy was significantly higher than that of acarbose therapy free. During the 10-year follow-up, a total of 446 endpoint events occurred, including all-cause death, cardiovascular events, cerebrovascular events. The incidences of myocardial infarction (from the 4th year of follow-up) and all-cause death (from the 2nd year of follow-up) in patients who received acarbose therapy were significantly lower than that of acarbose therapy free respectively. In Cox multivariate analyses, there were significant differences in incidences of myocardial infarction and all-cause death between afore two groups during the 10-year follow-up, and the adjusted HRs were 0.50 and 0.52, respectively. After multifactorial interventions, T2DM with acarbose therapy revealed significant reductions of myocardial infarction and all-cause death. The long-term effects of with acarbose therapy on improving joint target control might be one of the main reasons of myocardial infarction and all-cause death reduction. Trial Registration: ChiCTR-TRC-13003978, ChiCTR-OOC-15006090.Xue-Lian ZhangShen-Yuan YuanGang WanMing-Xia YuanGuang-Ran YangHan-Jing FuLiang-Xiang ZhuJian-Dong ZhangYu-Ling LiDa-yong GaoXue-Li CuiZi-ming WangRong-Rong XieYing-jun ChenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xue-Lian Zhang Shen-Yuan Yuan Gang Wan Ming-Xia Yuan Guang-Ran Yang Han-Jing Fu Liang-Xiang Zhu Jian-Dong Zhang Yu-Ling Li Da-yong Gao Xue-Li Cui Zi-ming Wang Rong-Rong Xie Ying-jun Chen The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24)
description	Abstract To investigate the potential benefits of acarbose therapy on cardiovascular events (CVD) in Type 2 diabetes (T2DM) in an urban community over 10-year follow-up. The study population of Beijing Community Diabetes Study (BCDS) were type 2 diabetes (T2DM) living in 21 communities in Beijing. All patients received comprehensive intervention in accordance with the Chinese guidelines for the prevention and treatment of diabetes. Professors in endocrinology from top tier hospitals regularly visited the communities for consultations, which was a feature of this study. A total of 1797 T2DM in BCDS study had complete screening data, including blood glucose, blood pressure, lipid profiles and acarbose continuous therapy. After 10-year follow-up, the risks of CVD outcomes were assessed according to whether patients had received acarbose therapy or not. All patients were followed-up to assess the long-term effects of the multifactorial interventions. At baseline, compared with the acarbose therapy free in T2DM, there was no significant difference in achieving the joint target control in patients with acarbose therapy. From the beginning of 8th year follow-up, the joint target control rate in patients with acarbose therapy was significantly higher than that of acarbose therapy free. During the 10-year follow-up, a total of 446 endpoint events occurred, including all-cause death, cardiovascular events, cerebrovascular events. The incidences of myocardial infarction (from the 4th year of follow-up) and all-cause death (from the 2nd year of follow-up) in patients who received acarbose therapy were significantly lower than that of acarbose therapy free respectively. In Cox multivariate analyses, there were significant differences in incidences of myocardial infarction and all-cause death between afore two groups during the 10-year follow-up, and the adjusted HRs were 0.50 and 0.52, respectively. After multifactorial interventions, T2DM with acarbose therapy revealed significant reductions of myocardial infarction and all-cause death. The long-term effects of with acarbose therapy on improving joint target control might be one of the main reasons of myocardial infarction and all-cause death reduction. Trial Registration: ChiCTR-TRC-13003978, ChiCTR-OOC-15006090.
format	article
author	Xue-Lian Zhang Shen-Yuan Yuan Gang Wan Ming-Xia Yuan Guang-Ran Yang Han-Jing Fu Liang-Xiang Zhu Jian-Dong Zhang Yu-Ling Li Da-yong Gao Xue-Li Cui Zi-ming Wang Rong-Rong Xie Ying-jun Chen
author_facet	Xue-Lian Zhang Shen-Yuan Yuan Gang Wan Ming-Xia Yuan Guang-Ran Yang Han-Jing Fu Liang-Xiang Zhu Jian-Dong Zhang Yu-Ling Li Da-yong Gao Xue-Li Cui Zi-ming Wang Rong-Rong Xie Ying-jun Chen
author_sort	Xue-Lian Zhang
title	The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24)
title_short	The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24)
title_full	The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24)
title_fullStr	The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24)
title_full_unstemmed	The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24)
title_sort	effects of acarbose therapy on reductions of myocardial infarction and all-cause death in t2dm during 10-year multifactorial interventions (the beijing community diabetes study 24)
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9dd8a1e1dbfc45a38f9200035a914351
work_keys_str_mv	AT xuelianzhang theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT shenyuanyuan theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT gangwan theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT mingxiayuan theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT guangranyang theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT hanjingfu theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT liangxiangzhu theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT jiandongzhang theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT yulingli theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT dayonggao theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT xuelicui theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT zimingwang theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT rongrongxie theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT yingjunchen theeffectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT xuelianzhang effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT shenyuanyuan effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT gangwan effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT mingxiayuan effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT guangranyang effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT hanjingfu effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT liangxiangzhu effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT jiandongzhang effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT yulingli effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT dayonggao effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT xuelicui effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT zimingwang effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT rongrongxie effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24 AT yingjunchen effectsofacarbosetherapyonreductionsofmyocardialinfarctionandallcausedeathint2dmduring10yearmultifactorialinterventionsthebeijingcommunitydiabetesstudy24
_version_	1718392930835628032

The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24)

Ejemplares similares